Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
  • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
  • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/42—Oxazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

• the present invention relates to new 4-methyl-1,3-oxazole compounds.
• acute-phase proteins a group of plasma proteins called acute-phase proteins. Some of these proteins--including fibrinogen, reactive protein C, haptoglobin--are increased during the acute-phase reaction, whereas others such as albumin and transferrin are reduced. The alteration of these proteins, in particular fibrinogen, is responsible for the modifications in the plasma viscosity and for the increase in the speed of sedimentation which are observed in the inflamation. Because of their correlation with clinical parameters during the development and the therapeutic remissions observed in rheumatoid arthritis, some of these acute- phase proteins have been used as a criterion for evaluating the disease (Mallya R. K. et al., J.
• R 1 represents a 1-adamantyl group, a dicyclopropylmethyl group, a (C 3 -C 6 ) cycloalkyl group (unsubstituted or substituted by a halogen atom, a hydroxy group, or a linear or branched (C 1 -C 6 ) alkoxy group) or a bicyclo[2.2.2]oct-1-yl group (unsubstituted or substituted at the 4-position by a halogen atom, a linear or branched (C 1 -C 6 ) alkoxy group or a hydroxy group),
• R 2 represents a group ##STR5## in which: m represents 1, 2 or 3,
• X represents an oxygen or sulfur atom or an N--R group (in which R is a hydrogen atom or a linear or branched (C 1 -C 6 ) alkyl group),
• R 3 or R 4 which are identical or different, represent a hydrogen atom, a linear or branched (C 1 -C 6 ) alkyl group, a trifluoromethyl group,
• R 5 represents a hydroxy group, a linear or branched (C 1 -C 6 ) alkoxy group, an amino group (unsubstituted or substituted by one or two linear or branched (C 1 -C 6 ) alkyl groups), or --O--CH 2 --CO--NRR' (such that R and R' represent a linear or branched (C 1 -C 6 ) alkyl group, or form with the nitrogen atom carrying them a 5- or 6-membered heterocycle),
• the invention also extends to the process for preparing the compounds of formula (I), wherein there is used as starting material an acid of formula (II):
• the invention also extends to the pharmaceutical compositions containing, as active ingredient, at least one compound of formula (I) or its optical isomers with one or more inert, non-toxic and appropriate excipients.
• the pharmaceutical compositions obtained can be provided in various forms, the most advantageous being tablets, sugar-coated tablets, hard gelatin capsules, suppositories, suspensions to be taken orally, the transdermal forms (gel, patch), and the like.
• the useful dosage can be adjusted according to the nature and severity of the condition, the route of administration as well as according to the age and the weight of the patient. This unit dosage ranges from 0.02 g to 2 g per day in one or more doses.
• the starting materials used are starting materials which are known or which are prepared according to known procedures.
• Stages A, B and C are identical to stages A, B and C of Example 1: 1-adamantanecarboxylic acid being replaced in stage A by dicyclopropylmethylcarboxylic acid.
• the expected product is obtained in the form of an oil after evaporation and purification by silica column chromatography, using as eluent a pentane/ethyl acetate mixture (85/15).
• Stages A to D of this example are carried out according to the same procedures as those described in stages A to D of Example 2.
• the biological activity of the compounds of the invention was determined in particular on the plasma albumin of rats 6 days after subcutaneous injection of complete Freund's adjuvant. Negative protein of the acute phase of the inflammation, albumin, which is substantially reduced by the inflammatory state which follows the adjuvant, is completely or partially restored by the compounds administered at the daily oral dose of 100 mg/kg.
• Adjuvant arthritis in rats described for the first time by Pearson (Pearson C. M., Proc. Soc. Exp. Biol. Med., 1956, 91, 95-101) was caused by injecting 0.1 ml of complete Freund's adjuvant (4 mg of Mycobacterium butyricum in suspension in 1 ml of paraffin oil/water/Tween 80) into the subplantar region of the hind legs of Lewis female rats (aged 62 days).
• the products were administered daily in the form of an aqueous solution or of a suspension in hydroxypropyl cellulose at 0.2% according to their solubility.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=9436452

Family Applications (1)

Country Status (8)

Cited By (2)

Families Citing this family (1)

Citations (6)

Family Cites Families (1)

• 1992
  • 1992-12-11 FR FR9214912A patent/FR2699172B1/fr not_active Expired - Fee Related
• 1993
  • 1993-12-09 US US08/164,464 patent/US5468761A/en not_active Expired - Fee Related
  • 1993-12-09 EP EP93402967A patent/EP0601930A1/fr not_active Withdrawn
  • 1993-12-09 AU AU52300/93A patent/AU665285B2/en not_active Ceased
  • 1993-12-10 JP JP5310639A patent/JP2579116B2/ja not_active Expired - Lifetime
  • 1993-12-10 CA CA002111152A patent/CA2111152A1/fr not_active Abandoned
  • 1993-12-10 ZA ZA939283A patent/ZA939283B/xx unknown
  • 1993-12-10 NZ NZ250417A patent/NZ250417A/en unknown

Patent Citations (6)

Also Published As

Similar Documents

Legal Events